GlaxoSmithKline agreed Thursday to release all data on the safety and effectiveness of its drugs to settle a lawsuit by New York's attorney general, who accused the pharmaceutical maker of withholding negative information about its antidepressant drug Paxil.
Glaxo will put summaries of all its studies since December 2000 in a clinical trial registry on its website. The London-based company is the first major drug maker to agree to disclose all its studies. The company also will pay $2.5 million to the state.
New York Atty. Gen. Eliot Spitzer sued the company in June, alleging the company fraudulently misled the public about the use of Paxil in children, specifically whether the drug increased suicidal tendencies in young people. The suit said Glaxo had conducted five studies on Paxil in children but disclosed only the study with the most favorable results.
Glaxo said the company still believed Spitzer's civil charge of fraud was unfounded but settled to avoid the cost of litigation.